0001193125-22-010128.txt : 20220118 0001193125-22-010128.hdr.sgml : 20220118 20220114191707 ACCESSION NUMBER: 0001193125-22-010128 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220114 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220118 DATE AS OF CHANGE: 20220114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cano Health, Inc. CENTRAL INDEX KEY: 0001800682 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39289 FILM NUMBER: 22533195 BUSINESS ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 BUSINESS PHONE: 2034227700 MAIL ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 FORMER COMPANY: FORMER CONFORMED NAME: Jaws Acquisition Corp. DATE OF NAME CHANGE: 20200121 8-K 1 d295580d8k.htm FORM 8-K Form 8-K
false 0001800682 0001800682 2022-01-14 2022-01-14 0001800682 us-gaap:CommonStockMember 2022-01-14 2022-01-14 0001800682 us-gaap:WarrantMember 2022-01-14 2022-01-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 14, 2022

 

 

CANO HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39289   98-1524224

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

9725 NW 117th Avenue, Suite 200

Miami, Florida 33178

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (855) 226-6633

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A Common Stock, par value $0.0001 per share   CANO   The New York Stock Exchange
Warrants to purchase one share of Class A Common Stock at an exercise price of $11.50   CANO WS   The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 1.01     Entry into a Material Definitive Agreement.

Amendment to Credit Agreement

On January 14, 2022, Cano Health, LLC, a Florida limited liability company and a subsidiary of Cano Health, Inc. (the “Company”), Primary Care (ITC) Intermediate Holdings, LLC, a Delaware limited liability company, Credit Suisse AG, Cayman Islands Branch, and the other lenders party thereto, entered into the Sixth Amendment (“Sixth Amendment”) to the Credit Agreement, dated as of November 23, 2020, pursuant to which the outstanding principal amount of approximately $644.4 million of senior secured term loans maturing November 23, 2027 (the “Existing Term Loans”) were replaced with an equivalent amount of new term loans (the “New Term Loans”) having substantially similar terms as the Existing Term Loans, except with respect to the interest rate applicable to the New Term Loans, with the implementation of a forward-looking term rate based on the secured overnight financing rate (“Term SOFR”) as the replacement of LIBOR as the benchmark interest rate for borrowings, and certain other provisions. The New Term Loans replaced the Existing Term Loans in full.

The interest rate applicable to the New Term Loans was revised to Term SOFR plus 4.00%, plus the applicable credit spread adjustment (with a Term SOFR floor of 0.50%). The interest rate applicable to the Existing Term Loans was LIBOR plus 4.50% (with a LIBOR floor of 0.75%). The maturity of the New Term Loans remains unchanged.

The forgoing description of the Sixth Amendment does not purport to be complete and is qualified in its entirety by the full text of the Sixth Amendment, a copy of which is filed as Exhibit 10.1 to this Form 8-K and is incorporated herein by reference.

Item 2.03.     Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Item 7.01.     Regulation FD Disclosure.

On January 14, 2022, the Company issued a press release announcing the closing of the repricing of the New Term Loans. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01     Financial Statements and Exhibits

(d) Exhibits:

 

Exhibit
Number		   

Description

10.1    Sixth Amendment to Credit Agreement, dated as of January 14, 2022.
99.1    Press release of Cano Health, Inc. dated January 14, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CANO HEALTH, INC.
Date: January 14, 2022     By:  

/s/ Dr. Marlow Hernandez

    Name:   Dr. Marlow Hernandez
    Title:   Chief Executive Officer and President
 EX-10.1 2 d295580dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

SIXTH AMENDMENT TO CREDIT AGREEMENT

This SIXTH AMENDMENT TO CREDIT AGREEMENT, dated as of January 14, 2022 (as it may be amended from time to time, this “Sixth Amendment”), by and among CANO HEALTH, LLC, a Florida limited liability company (the “Borrower”), PRIMARY CARE (ITC) INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH (“Credit Suisse”), as administrative agent and collateral agent (in such capacity, together with its permitted successors and assigns in such capacity, the “Administrative Agent”) under the Loan Documents, each of the Revolving Lenders, each of the Issuing Banks and each of the Persons party hereto as 2022 Replacement Term Lenders (in each case as defined below).

W I T N E S S E T H:

WHEREAS, the Borrower, Holdings, each Lender and Issuing Bank party thereto from time to time, the Administrative Agent, and Credit Suisse, as an Issuing Bank, have entered into that certain Credit Agreement, dated as of November 23, 2020 (as may be amended, restated, amended and restated, modified and/or supplemented from time to time through, but not including, the date hereof, the “Credit Agreement”; capitalized terms not otherwise defined in this Sixth Amendment have the same meanings assigned thereto in the Credit Agreement);

WHEREAS, on the date hereof (but prior to giving effect to this Sixth Amendment), there are outstanding Initial Term Loans under the Credit Agreement (for purposes of this Sixth Amendment, herein called the “Original 2020 Replaced Term Loans”) in an aggregate principal amount of $644,432,743.72;

WHEREAS, in accordance with the provisions of Section 1.09 and Section 9.02(c)(i) of the Credit Agreement, the Borrower desires to amend the Credit Agreement to enable the Borrower to refinance in full the outstanding Original 2020 Replaced Term Loans with the proceeds of 2022 Replacement Term Loans (as defined below) as more fully provided herein;

WHEREAS, as contemplated by Section 1.09 and Section 9.02(c)(i) of the Credit Agreement, the parties hereto have agreed to amend certain terms of the Credit Agreement as hereinafter provided to give effect to the 2022 Replacement Term Loans (as defined below), subject to the satisfaction of the conditions precedent in Section 6 hereof;

WHEREAS, in accordance with Section 9.02(d)(ix)(A) of the Credit Agreement, the Borrower and the Revolving Lenders desire to amend the Credit Agreement to provide for the replacement of the Adjusted LIBO Rate (solely as it relates to the Initial Revolving Facility) with Adjusted Term SOFR (as defined in the Amended Credit Agreement) as more fully provided herein;

WHEREAS, the Credit Agreement may be waived, amended or modified pursuant to an agreement or agreements in writing entered into by the Borrower, the Administrative Agent and the Lenders required pursuant to the terms of Section 9.02 of the Credit Agreement;

WHEREAS, the (i) establishment of the 2022 Replacement Term Loans and (ii) amendment of certain terms and conditions of the Credit Agreement as provided herein are collectively referred to herein as the “Sixth Amendment Transaction”;

WHEREAS, each Loan Party as of the Sixth Amendment Closing Date (collectively, the “Reaffirming Parties” and each a “Reaffirming Party”) expects to realize substantial direct and indirect benefits as a result of this Sixth Amendment becoming effective and the consummation of the Sixth Amendment Transaction and agrees to reaffirm its obligations pursuant to the Credit Agreement (in the case of Holdings and the Borrower), the Guarantee Agreement, the Collateral Documents and the other Loan Documents to which it is a party; and

WHEREAS, Credit Suisse Loan Funding LLC, Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A. and Morgan Stanley Senior Funding, Inc. will act as joint lead arrangers and joint bookrunners, and have agreed to act, as joint lead arrangers and joint bookrunners for the 2022 Replacement Term Loans (in such capacities, the “Sixth Amendment Lead Arrangers”).

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

SECTION 1. Defined Terms. Capitalized terms used but not defined herein (including in the preamble and the recitals hereto) shall have the meanings assigned to them in the Credit Agreement, as amended hereby (regardless of whether such amendments have taken effect).

SECTION 2. Replacement Term Loans

(a)(i) Subject to the terms and subject to the conditions set forth herein and in the Credit Agreement (as amended hereby), the 2022 Replacement Term Lenders hereby severally agree to make 2022 Replacement Term Loans in Dollars to the Borrower on the Sixth Amendment Closing Date (as defined below) in the aggregate principal amount of $644,432,743.72 to refinance all outstanding Original 2020 Replaced Term Loans in accordance with the relevant requirements of the Amended Credit Agreement (as defined below) and this Sixth Amendment. It is understood and agreed that the 2022 Replacement Term Loans being made pursuant to this Sixth Amendment and the Amended Credit Agreement shall constitute “Replacement Term Loans” as defined in, and pursuant to, Section 9.02(c)(i) of the Credit Agreement and the Original 2020 Replaced Term Loans being refinanced shall constitute “Replaced Term Loans” as defined in, and pursuant to, Section 9.02(c)(i) of the Credit Agreement. Except as expressly provided in this Sixth Amendment (including as to the Applicable Rate) and the Amended Credit Agreement, the 2022 Replacement Term Loans shall be on terms identical to the Original 2020 Replaced Term Loans (including as to maturity, Guarantors, Collateral (and ranking) and payment priority).

(ii) On the Sixth Amendment Closing Date, all then outstanding Original 2020 Replaced Term Loans shall be refinanced in full as follows:

(w) The outstanding principal amount of the Original 2020 Replaced Term Loans of each Lender which (i) is an existing Lender under the Credit Agreement prior to giving effect to this Sixth Amendment (each, an “Existing Lender”) and (ii) is not party hereto as a 2022 Replacement Term Lender (a Lender meeting the requirements of clauses (i) and (ii), each, a “Non- Converting Lender”) shall be repaid in full in Cash.

(x) To the extent any Existing Lender has a 2022 Replacement Term Loan Conversion Amount (as defined in the Amended Credit Agreement) that is less than the full outstanding principal amount of the Original 2020 Replaced Term Loan of such Lender, such Lender shall be repaid in Cash in an amount equal to the difference between the outstanding principal amount of the Original 2020 Replaced Term Loan of such Lender and such Lender’s 2022 Replacement Term Loan Conversion Amount (the “Non-Converting Portion”).

 

2

(y) The outstanding principal amount of the Original 2020 Replaced Term Loan of each Existing Lender which has executed this Sixth Amendment as a “2022 Converting Lender” (each, a “2022 Converting Lender”) shall automatically be converted into a term loan (each, a “Converted 2022 Replacement Term Loan”) in a principal amount equal to such 2022 Converting Lender’s 2022 Replacement Term Loan Conversion Amount (each such conversion, a “2022 Term Loan Conversion”).

(z) Each Person that has executed this Sixth Amendment as a “New 2022 Replacement Lender” (each, a “New 2022 Replacement Lender” and, together with the 2022 Converting Lenders, collectively, the “2022 Replacement Term Lenders”) severally agrees to make to the Borrower a new term loan (each, a “New 2022 Replacement Term Loan” and, collectively, the “New 2022 Replacement Term Loans” and, together with the Converted 2022 Replacement Term Loans, the “2022 Replacement Term Loans”) in Dollars in a principal amount equal to the amount set forth opposite such New 2022 Replacement Lender’s name on Schedule I hereto (as to any New 2022 Replacement Lender, its “2022 Replacement Term Loan Commitment”) on the Sixth Amendment Closing Date.

(iii) Each 2022 Replacement Term Lender hereby agrees to “fund” its 2022 Replacement Term Loan as follows: (x) each 2022 Converting Lender shall “fund” its 2022 Replacement Term Loan to the Borrower by converting all or a portion of its then outstanding principal amount of Original 2020 Replaced Term Loan into a 2022 Replacement Term Loan in a principal amount equal to such 2022 Converting Lender’s 2022 Replacement Term Loan Conversion Amount as provided in clause (ii)(y) above and (y) each New 2022 Replacement Lender shall fund in Cash to the Borrower in an amount equal to such New 2022 Replacement Term Lender’s 2022 Replacement Term Loan Commitment.

(iv) On the Sixth Amendment Closing Date, the Borrower shall pay in Cash (a) all accrued and unpaid interest on the Original 2020 Replaced Term Loans through the Sixth Amendment Closing Date and (b) to each Non-Converting Lender and each 2022 Converting Lender with a Non-Converting Portion (solely with respect to such Non-Converting Portion), any breakage loss or expenses due under Section 2.15 of the Credit Agreement. Notwithstanding anything to the contrary herein or in the Credit Agreement, each 2022 Converting Lender agrees, and each Existing Lender agrees (by execution of an Assignment and Assumption with respect to any 2022 Replacement Term Loans), to waive any entitlement to any breakage loss or expenses due under Section 2.15 of the Credit Agreement with respect to the repayment of any Original 2020 Replaced Term Loans of any such Lender with the proceeds of 2022 Replacement Term Loans on the Sixth Amendment Closing Date.

(v) Promptly following the Sixth Amendment Closing Date, all Promissory Notes, if any, evidencing the Original 2020 Replaced Term Loans shall be cancelled and returned to the Borrower, and any 2022 Replacement Term Lender may request that its 2022 Replacement Term Loan be evidenced by a Promissory Note pursuant to Section 2.09(f) of the Credit Agreement.

(vi) Notwithstanding anything to the contrary contained in the Credit Agreement, all proceeds of the New 2022 Replacement Term Loans (if any) will be used solely to repay outstanding Original 2020 Replaced Term Loans of Non-Converting Lenders (if any) and outstanding Original 2020 Replaced Term Loans of 2022 Converting Lenders in an amount equal to the Non-Converting Portion (if any) of such 2022 Converting Lenders’ Original 2020 Replaced Term Loans, in each case, on the Sixth Amendment Closing Date.

 

3

(b) The Borrower hereby consents, for purposes of Section 9.05(b)(i)(A) of the Credit Agreement, to the assignment of any 2022 Replacement Term Loans by any New 2022 Replacement Lender to any Person that was an Existing Lender on the Sixth Amendment Effective Date (immediately prior to giving effect thereto).

SECTION 3. Amendments to the Credit Agreement. (a) The Credit Agreement is, effective as of the Sixth Amendment Closing Date, and subject to the satisfaction of the conditions precedent set forth in Section 6 hereof, hereby amended to delete the stricken text (indicated textually in the same manner as the following example: stricken text) and to add the double-underlined text (indicated textually in the same manner as the following example: double-underlined text) as reflected by the credit agreement attached hereto as Exhibit A (the Credit Agreement, as so amended, the “Amended Credit Agreement”).

(b) For the avoidance of doubt, the interest rates under the Credit Agreement (including, for the avoidance of doubt, the Applicable Rate and the applicable interest rate benchmarks) shall be determined (i) for all periods prior to the Sixth Amendment Closing Date, in accordance with the provisions of the Credit Agreement (as in effect prior to the Sixth Amendment Closing Date) and (ii) for all periods on and after the Sixth Amendment Closing Date, in accordance with the provisions of the Credit Agreement (as in effect on the Sixth Amendment Closing Date).

(c) Exhibits B and D to the Credit Agreement are, effective as of the Sixth Amendment Closing Date, and subject to the satisfaction of the conditions precedent set forth in Section 6 hereof, hereby amended and restated as set forth in Exhibit B hereto.

SECTION 4. Representations and Warranties. To induce the other parties hereto to enter into this Sixth Amendment, each of Holdings and the Borrower represents and warrants to the Administrative Agent, the Revolving Lenders and the 2022 Replacement Term Lenders that:

(a) as of the Sixth Amendment Closing Date, after giving effect to this Sixth Amendment and the Sixth Amendment Transaction, all of the representations and warranties of the Loan Parties set forth in this Sixth Amendment and the other Loan Documents are true and correct in all material respects (or, if qualified by materially, in all respects) on and as of the Sixth Amendment Closing Date; provided that to the extent that any representation and warranty specifically refers to a given date or period, it shall be true and correct in all material respects (or, if qualified by materially, in all respects) as of such date or for such period; and

(b) no Event of Default has occurred and is continuing at the time of, or immediately after giving effect to, the establishment of the 2022 Replacement Term Loans on the Sixth Amendment Closing Date.

SECTION 5. [Reserved]

SECTION 6. Conditions to the Sixth Amendment Closing Date. The effectiveness of the amendments in Section 3 hereof and the establishment of the 2022 Replacement Term Loans is subject to the satisfaction (or waiver by the Lenders party hereto) of the following conditions precedent (the first date of the satisfaction thereof is referred to as the “Sixth Amendment Closing Date”):

(a) Sixth Amendment. The Administrative Agent (or its counsel) shall have received a counterpart of this Sixth Amendment signed by each of (i) the Borrower and Holdings (or written evidence reasonably satisfactory to the Administrative Agent (which may include a copy transmitted by facsimile or other electronic method) that each such Loan Party has signed a counterpart), (ii) the Revolving Lenders and (iii) the 2022 Replacement Term Lenders.

 

4

(b) Representations and Warranties; Absence of Events of Default. All of the representations and warranties of the Loan Parties set forth in this Sixth Amendment and the other Loan Documents shall be true and correct in all material respects (or, if qualified by materiality, in all respects) as of the Sixth Amendment Closing Date; provided that to the extent that any representation and warranty specifically refers to a given date or period, it shall be true and correct in all material respects (or, if qualified by materiality, in all respects) as of such date or for such period. No Event of Default shall have occurred and be continuing at the time of, or immediately after giving effect to, the establishment of the 2022 Replacement Term Loans on the Sixth Amendment Closing Date.

(c) Legal Opinions. The Administrative Agent shall have received, on behalf of itself and the Lenders on the Sixth Amendment Closing Date, a customary written opinion of (i) Goodwin Procter LLP, in its capacity as counsel for the Loan Parties and (ii) Hill Ward Henderson, in its capacity as Florida counsel for the applicable Loan Parties, in each case, dated the Sixth Amendment Closing Date and addressed to the Administrative Agent and the Lenders and with respect to this Sixth Amendment and the other Loan Documents executed on the Sixth Amendment Closing Date.

(d) Secretary’s Certificates and Good Standing Certificates. The Administrative Agent shall have received (i) a certificate of each Loan Party, each dated the Sixth Amendment Closing Date and executed by a secretary, assistant secretary or other Responsible Officer thereof, which shall (A) certify that (1) attached thereto is a true and complete copy of the certificate or articles of incorporation, formation or organization (or equivalent) of such Loan Party certified by the relevant authority of its jurisdiction of organization (to the extent reasonably available in the applicable jurisdiction), (2) the certificate or articles of incorporation, formation or organization (or equivalent) of such Loan Party attached thereto have not been amended (except as attached thereto) since the date reflected thereon, (3) attached thereto is a true and correct copy of the by-laws or operating, management, partnership or similar agreement of such Loan Party, together with all amendments thereto as of the Sixth Amendment Closing Date, and such by-laws or operating, management, partnership or similar agreement are in full force and effect as of the Sixth Amendment Closing Date and (4) attached thereto is a true and complete copy of the resolutions or written consent, as applicable, of its board of directors, board of managers, sole member or other applicable governing body authorizing the execution and delivery of the Loan Documents, which resolutions or consent have not been modified, rescinded or amended (other than as attached thereto) and are in full force and effect, and (B) identify by name and title and bear the signatures of the officers, managers, directors or authorized signatories of such Loan Party authorized to sign the Loan Documents to which such Loan Party is a party on the Sixth Amendment Closing Date and (ii) a good standing (or equivalent) certificate as of a recent date for each Loan Party from the relevant authority of its jurisdiction of organization (to the extent applicable in such jurisdiction).

(e) Officer’s Certificate. The Administrative Agent shall have received a certificate, dated the Sixth Amendment Closing Date and executed by a Responsible Officer of the Borrower, certifying as to the satisfaction of the conditions set forth in Sections 6(b) and 6(i).

(f) Solvency. The Administrative Agent shall have received a certificate in substantially the form attached as Exhibit L to the Credit Agreement (with references therein to the “Transactions” being updated to refer to the “Sixth Amendment Transaction”) from the chief financial officer (or other Responsible Officer with reasonably equivalent responsibilities) of the Borrower dated as of the Sixth Amendment Closing Date and certifying as to the matters set forth therein.

 

5

(g) Fees. Prior to or substantially concurrently with the establishment of the 2022 Replacement Term Loans, the Replacement Term Lenders, the Administrative Agent and the Sixth Amendment Lead Arrangers shall have received all fees and reimbursement of all reasonable out-of-pocket expenses (including reasonable legal fees and expenses), in each case required to paid or reimbursed by the Borrower and for which invoices in reasonable detail have been presented at least three (3) Business Days prior to the Sixth Amendment Closing Date (or such later date to which the Borrower may agree).

(h) USA PATRIOT Act and Beneficial Ownership Certification. The Administrative Agent shall have received at least three (3) Business Days prior to the Sixth Amendment Closing Date (or such later date to which the Borrower and the Administrative Agent may agree) all documentation and other information about the Borrower and the Guarantors as has been reasonably requested in writing at least 10 days prior to the Sixth Amendment Closing Date (or such later date to which the Borrower and the Administrative Agent may agree) by the Administrative Agent (on behalf of itself and the Lenders) and that the Administrative Agent reasonably determines is required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including without limitation the USA PATRIOT Act. No later than three (3) Business Days prior to the Sixth Amendment Closing Date, if the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation and the Administrative Agent has so requested the Borrower in writing at least 10 days prior to the Sixth Amendment Closing Date, then the Borrower shall have delivered to the Administrative Agent a Beneficial Ownership Certification in relation to the Borrower.

(i) Replacement Term Loans. The incurrence of the 2022 Replacement Term Loans shall be permitted under Section 9.02(c)(i) of the Credit Agreement.

(j) Reaffirmation by the Loan Parties. The Administrative Agent shall have received a customary reaffirmation agreement, dated as of the Sixth Amendment Closing Date (the “Reaffirmation Agreement”) and executed by each Reaffirming Party, whereby it agrees to reaffirm its obligations pursuant to the Credit Agreement (in the case of Holdings and the Borrower), the Guarantee Agreement, the Collateral Documents and the other Loan Documents to which it is a party.

(k) Borrowing Notice. The Administrative Agent (or its counsel) shall have received from the Borrower, a Borrowing Request in respect of the 2022 Replacement Term Loans in accordance with Sections 2.03 of the Credit Agreement not later than 12:00 p.m., New York City time, one (1) Business Day before the Sixth Amendment Closing Date (or such later time as the Administrative Agent may agree).

(l) Revolving Loans. Prior to or substantially concurrently with the establishment of the 2022 Replacement Term Loans, the Revolving Lenders shall have received all accrued and unpaid interest and fees with respect to the Revolving Facility on such date.

SECTION 7. Reference to and Effect on the Credit Agreement and the other Loan Documents.

(a) On and after the Sixth Amendment Closing Date, each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof” or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement, as amended by this Sixth Amendment.

(b) The Credit Agreement and each of the other Loan Documents, as specifically amended by this Sixth Amendment, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed. Without limiting the generality of the foregoing, the Collateral Documents and all of the Collateral described therein do and shall continue to secure the payment of all Obligations of the Loan Parties, as amended by this Sixth Amendment (including any such Obligations in respect of the 2022 Replacement Term Loans).

 

6

(c) On and after the effectiveness of this Sixth Amendment, this Sixth Amendment shall constitute a “Loan Document” for all purposes of the Credit Agreement (as amended by this Sixth Amendment) and the other Loan Documents.

(d) This Sixth Amendment is limited as specified and shall not constitute an amendment, modification, acceptance, waiver or a novation of any other provision of the Credit Agreement or any other Loan Document.

SECTION 8. Execution in Counterparts. This Sixth Amendment may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Any signature to this Sixth Amendment may be delivered by facsimile, electronic mail (including pdf) or any electronic signature complying with the U.S. Federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes to the fullest extent permitted by applicable law. For the avoidance of doubt, the foregoing also applies to any amendment, extension or renewal of this Sixth Amendment. Each of the parties represents and warrants to the other parties that it has the corporate capacity and authority to execute this Sixth Amendment through electronic means and there are no restrictions for doing so in that party’s constitutive documents.

SECTION 9. Severability. Section 9.08 of the Credit Agreement is incorporated by reference herein as if such Section appeared herein, mutatis mutandis.

SECTION 10. Governing Law; Submission to Jurisdiction; Waiver of Jury Trial, Etc. THIS SIXTH AMENDMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE (WHETHER IN TORT, IN CONTRACT, AT LAW OR IN EQUITY OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATED TO THIS SIXTH AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. SECTIONS 9.10(b), (c) and (d) AND 9.11 OF THE CREDIT AGREEMENT ARE INCORPORATED BY REFERENCE HEREIN AS IF SUCH SECTIONS APPEARED HEREIN, MUTATIS MUTANDIS.

SECTION 11. Headings. Section headings herein are included for convenience of reference only and shall not affect the interpretation of this Sixth Amendment.

[The remainder of this page is intentionally left blank]

 

7

IN WITNESS WHEREOF, the parties hereto have caused this Sixth Amendment to be executed by their respective officers thereunto duly authorized, as of the date first above written.

 

CANO HEALTH, LLC, as Borrower
By:  

/s/ Brian Koppy

  Name:   Brian Koppy
  Title:   Chief Financial Officer
PRIMARY CARE (ITC) INTERMEDIATE HOLDINGS, LLC, as Holdings
By:  

/s/ Brian Koppy

  Name:   Brian Koppy
  Title:   Chief Financial Officer

 

 

[Signature Page to Sixth Amendment to Credit Agreement]

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative Agent, a Revolving Lender, an Issuing Bank and as the New 2022 Replacement Term Lender
By:  

/s/ Vipul Dhadda

  Name:   Vipul Dhadda
  Title:   Authorized Signatory
By:  

/s/ Jessica Gavarkovs

  Name:   Jessica Gavarkovs
  Title:   Authorized Signatory

 

[Signature Page to Sixth Amendment to Credit Agreement]

GOLDMAN SACHS BANK USA, as a Revolving Lender and as an Issuing Bank
By:  

/s/ Dan Martis

  Name:   Dan Martis
  Title:   Authorized Signatory

 

[Signature Page to Sixth Amendment to Credit Agreement]

JPMORGAN CHASE BANK, N.A., as a Revolving Lender and as an Issuing Bank
By:  

/s/ Helen D. Davis

  Name:   Helen D. Davis
  Title:   Authorized Officer

 

[Signature Page to Sixth Amendment to Credit Agreement]

MORGAN STANLEY SENIOR FUNDING, INC., as a
Revolving Lender and an Issuing Bank
By:  

/s/ Mark Scioscia

  Name:   Mark Scioscia
  Title:   Authorized Signatory

 

[Signature Page to Sixth Amendment to Credit Agreement]

EX-99.1 3 d295580dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Cano Health Announces Repricing of Term Loan

Company completes opportunistic repricing

MIAMI, FL., Jan. 14, 2022— Cano Health, Inc. (NYSE: CANO) announced today that its wholly-owned subsidiary, Cano Health, LLC (“Cano Health”), completed a repricing of its approximately $644.4 million senior secured Term Loan B maturing November 23, 2027 (the “Term Loan”).

The Term Loan will bear interest using a forward looking-term rate based on the secured overnight financing rate (“Term SOFR”), replacing LIBOR as the reference rate. Based on current Term SOFR rates, the overall pricing of the Term Loan was reduced by 0.75% to the sum of (i) Term SOFR plus a credit spread adjustment (“CSA”) and (ii) 4.00%, with a Term SOFR plus CSA floor of 0.50%. Previously, the Term Loan was priced at LIBOR plus 4.50% with a LIBOR floor of 0.75%.

About Cano Health

Cano Health operates value-based primary care medical centers and supports affiliated medical practices that specialize in primary care for seniors in Florida, Texas, Nevada, New York, New Jersey, New Mexico, California, Illinois, and Puerto Rico, with additional markets in development. As part of its care coordination strategy, Cano Health provides sophisticated, high-touch population health management programs including telehealth, prescription home delivery, wellness programs, transition of care, and high-risk and complex care management.

Cano Health’s personalized patient care and proactive approach to wellness and preventive care sets it apart from competitors. Cano Health has consistently improved clinical outcomes while reducing costs, affording patients the opportunity to lead longer and healthier lives. Cano Health serves a predominantly minority population (80% of its patients are Latino or African American) and low-income population (50% of its members are dual eligible for Medicare and Medicaid). For more information visit www.canohealth.com or www.canohealth.com/investors/.

Investor Relations Contacts:

Alan Oshiki or Sydney Isaacs

Abernathy MacGregor

(212) 371-5999 / (713) 817-9346

aho@abmac.com / sri@abmac.com

Media Relations Contact:

Patricia Graue

Brunswick Group

(212) 333-3810

canohealth@brunswickgroup.com

EX-101.SCH 4 cano-20220114.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 5 cano-20220114_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 cano-20220114_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Warrant [Member] Warrant [Member] EX-101.PRE 7 cano-20220114_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 g295580cano-20211109_g1.jpg GRAPHIC begin 644 g295580cano-20211109_g1.jpg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htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 14, 2022
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001800682
Document Type 8-K
Document Period End Date Jan. 14, 2022
Entity Registrant Name CANO HEALTH, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39289
Entity Tax Identification Number 98-1524224
Entity Address, Address Line One 9725 NW 117th Avenue
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33178
City Area Code (855)
Local Phone Number 226-6633
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Class A Common Stock, par value $0.0001 per share
Trading Symbol CANO
Security Exchange Name NYSE
Warrant [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Warrants to purchase one share of Class A Common Stock at an exercise price of $11.50
Trading Symbol CANO WS
Security Exchange Name NYSE
XML 10 d295580d8k_htm.xml IDEA: XBRL DOCUMENT 0001800682 2022-01-14 2022-01-14 0001800682 us-gaap:CommonStockMember 2022-01-14 2022-01-14 0001800682 us-gaap:WarrantMember 2022-01-14 2022-01-14 false 0001800682 8-K 2022-01-14 CANO HEALTH, INC. DE 001-39289 98-1524224 9725 NW 117th Avenue Suite 200 Miami FL 33178 (855) 226-6633 false false false false Class A Common Stock, par value $0.0001 per share CANO NYSE Warrants to purchase one share of Class A Common Stock at an exercise price of $11.50 CANO WS NYSE true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 3 118 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d295580d8k.htm cano-20220114.xsd cano-20220114_def.xml cano-20220114_lab.xml cano-20220114_pre.xml d295580dex101.htm d295580dex991.htm http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d295580d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "cano-20220114_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "d295580d8k.htm" ] }, "labelLink": { "local": [ "cano-20220114_lab.xml" ] }, "presentationLink": { "local": [ "cano-20220114_pre.xml" ] }, "schema": { "local": [ "cano-20220114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 2, "nsprefix": "cano", "nsuri": "http://www.canohealth.com/20220114", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d295580d8k.htm", "contextRef": "duration_2022-01-14_to_2022-01-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d295580d8k.htm", "contextRef": "duration_2022-01-14_to_2022-01-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "cano_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.canohealth.com/20220114", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "cano_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.canohealth.com/20220114", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.canohealth.com//20220114/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001193125-22-010128-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-010128-xbrl.zip M4$L#!!0 ( "*:+E1/RLL6\P, *4/ 1 8V%N;RTR,#(R,#$Q-"YX MGF1:1T@N<68WMJF 8G$+P8IK3H /],6X' XUP%M,"Y\3,/*BQN/+$89R$ M9TD'1XE4&YNYA24CPBY]IUQYXB1YWX%DC+<(3\TP&BW4 P;#_DV<%]^?TB". MSS",AX6JLPY$N^- M"B\(*?86V!FV4R?6:CXK+;M1.A^Q.2D%[%?*?THB^)RSS'O!P.=,V@V?30]+ M](+9.Y(S4Q#*CFP6C.:^FD":"?[KZ^TW/[7!E0,@Y >9YX72%E7S?*NH_\QZ M6N'>PJ:#H5L*DP$4(8)@ 9)[>3_3?H1?3*09C).(M%-U,!'SW#?@'L+U1#S' MH>_[.;D:VS+A:G'A:I%\.*@6.S+S"DR4O'LIF8Y6MH1.[)(DG#I!3#Y6CZ%[ M/*)3:_Q+>]71&U>9\][MMP7JF%U]@+V:A9FPIEDY8&;[A.^5&?F#ZTA*.X== MS9*BX'*NZB58=$*0-FHP87/DCX^4:*J58/V'#"ZT*IBV'%BL M!:4*L-1L/@R<:H>-5M\+,HM JQN7G0TV)^=6;D['!W M(:(-[2HS# QT170D[C].M]#LV'0!8N",]&U[/NL_.E[_U^0S-C\V>8!PR?M3 M'[4^1R?N]IB"!W(/WR?CONM%>[_ ECPIJ?)517&D:.DN,^(P'BXMS8;HN@Y72>S^X$=&$Z'[2&2&JG"H$^\2;P?9CE\: MEOTNK_PS)8*6HIVW&EQ[] &W)_5PY&:;]^/JU:9EC8+A;0FK5S:ES@M=?=OT MO7#-O>_KP93,W,0XM841^[%C-6C^KI\:N/O*Q=BRW#$-D"EG!E#^!]47K860^'):ZRJ0^8E;J>(,F%<%L- ZM+"$H@IB;4-N_XQ$2A MXGYW<3$N8I?Y4TJQ97!RN\_@M02P,$% @ (IHN5%UL>NSD!0 MY3< !4 !C86YO+3(P,C(P,3$T7V1E9BYX;6SEFUMSXC84Q]\[T^^@>E_: MF1K;$-*&"=VAN>PPS6T2MMOI2T;8 C0K2XPD!_CVE825<#'$3E;97?<),#I' MO[\L'Q^?,SY^/T\)>$!<8$:[7M0(/8!HS!),QUTO$SX4,<;>^S]^_.'X)]\' MI^?]*^"#B913T0F"V6S62$:8"D8RJ3R(1LS2 /B^'7\R^ C^7GKO@%M$$!0( MI%!(Q,&?&29)IQDVH_"P&36:JV8<0>T/)%"B#HB"J!VH@4UPT(FB3G@(>I?@ MS'BA8(!3M&K*I@N.QQ,)?HY_ <;HE%&*"$$+<(XII#&&!-Q9XE]!G\8-T",$ MW&HSH3 %X@\H:>1>"::?AYI;+14574^+S[7/AYPT&!\KN+ 5V('>AA 2P1$N>!Q-D3^X]I40RUTD ,;((N\Z5&SQ9"R"8)$3DQT-H$TC**#0,(YHRQ= M!&:.4Q9GRK>TGSV:G%&)Y:)/1XRG)A2LZ]>.?>O-"+U5CNZK.%I?W%5%:I]C MBO78"_5S;3B:2T03E%@G&M^98H-DH0B+GUD!?>1^G\,!'#[MHZ4>H@,MX_8@ M@4-$EK[+> J^-*%:;]27*!5?A'+%VW[2U6M@!,707 @J QE#.-5G, P0D<(> MT9I"/XSR6\F[_/#]G509@V8Y(5"(Z]&=9/'GWAR7$E/"R5MH6)WU- ^AY>&+ MK+]'ZOOF&W&S-&743'R9WPHJ8&\;OP7S)\@YI+(Z[X;A\ZS"P@H4-\;L(4@0 M7G*J+YMXZM!]3UTWB;YVS@DXV)RQ3NVMQPI**S,^X+1^NH6^8D)#\BZ?58UFQ!P? ^B3V.()5$-=M'$#I M>ANYF3!:,:YNVSF ^\2Q5$_=.M_-:!X/2SU3[3%V@'G'"(ZQQ'1\J;8]QY"4 M92RR= !XPY%>!J0N19.SZ4(&OQZ-RI_N?1[< _>%R!!_/7:!'Q?; <69VGN+ MJ#D<8%FN[E)LYP!NP*%NL]PMTB$KO4TWC!RNV=D\GD Z1E72Z&);9W>+SF%O+8 MNLQKRB5;(DN;$6=IM5I?/CDK7\=D7(6"KJ<2UJF2I7=1UU/I8"84*IOJ@2:8 MF])Z)V94HKD\(R:8=#V!QOK+T_^$"91T/6+L&Q_O3+7V&Q];9&VV>9 I:YO/NILA&'XE<[H>A>L2.B>RB[; M6PJU\@Z^;V4;15.KJOVMJ7I9?"ZHOUJ%OS6^P5WY_U4KM>%LY% MMEKU%+E17;9J#^JEMKA*;<6VZRCVF?*VU7Y81^VKI7(KM)8A>6>EW:JN66C> M4ZRWBH_^'XJ?AO$BJQ9 MHK7=4K%":Y9D[>C,6+4U2ZN*>CQ6:LT2JWU=(BNY9EG5\QTF*[QFR=5VMRH7 MVJY93K71_+(J:Y9)%3?1K-A:9E [NG!6<\U2J-V=/"NX=#IU;%[!VGA90K^T M]OAJEOKQ'U!+ P04 " BFBY4)Z^ GOX' ! 7 %0 &-A;F\M,C R M,C Q,31?;&%B+GAM;,V<7V_;-A3%WPOT.]QY+QM0_VTWH$;3PG/2(5C2!(V[ M#BN&0I9IAZA$&I2*DM8K:7N13VH(H]MC,"S@C)ZT-B5H?WK]\\>ZG=AM. M/YY_@C; M1"#THI@(^&-%@]EPT!OT>[\/^IU!?IH@GM*#F1>3(?2[_=^ZFW+_6$_IOW[[MZKWYT1$UC97B_>X_EQ%4R/CC+*."9N15/E!F_OIJ%M!YHFJ8D]+1L3O M+/A==T:H J2G7K35BW:OG_;YL]ST?K!NI <9%MU%9.6H9) MW>VVU+B1\+>T/.%G.O+E@:.0CNCZ7/[TEG%;*V;3YX*'QB[2-YK&T M[18#RC,6TW@SEL6$%YS+4_+Z+[*QA;-@=QKMX_!MBGW%^I#$VD!UN>M^*DP+N^R%&S7PJ7?J15#%([P@Q>,T6PF;43I/Q>4D7ZU4!@%&@U$ MF25^8&#](!2*XH8@U7^5O0!5":X8ULK&F0U# ([PXC( @[H!&#R[ QL S!P M$8#!TP5@S@4Z[/H]\Y6X%OR.,K_BI9\BC>> ?9$Q$_L[8]$" M8-1UE(+DXH<$**N&&P4G5LKR4,$/>BBN>11[P;]T6?UJJ%GA.03";,H4AZV1 M:&$PJ#J*0E()9"G,*YSN;)3%P-H+RGV%RJ8@7A7LM^AJ7&^OZ_6/85[ M.DCXZM_\2AF'5OP^M^XGM&P6 T=UTV]P?OK^_,:PK+0 #?OKX.G60L) M42T.6AWK"J.;?O.H5FD: ]>O@L8Q86,>ABN67K^,;)DMF-P0N.56>,F@.@B7 M"")QG%: [1*U67;8>![HJMUC0'W# ^K3F++%I5R/"^H%MD2;9C:$"J*P0"8>^QU(]CR.NYG/[I4290D,P M6YCBAT;6@?N0*A+DL@SDZT!2"'2EVKB[-I''_D@G#@)P'D4K(NK'P*#S/,)0 M;- B95'IDPSVWX M7&HTPHO'8)Q3]_6PSZM9!9Q')MSU;3R_6C:/]]G@64C$0B;H3\'OXUNY2%EZ MK.)CQ 42C7XZ6&Z+'QQ:__/!$EDDXM,/U;)"D%2"M!32YX,.;1@^(*SL!3$( M:_F[A$5477U,GL2KF +#_&8C4&R(EX]#@+] $YG\-3R621^?Q,+>D0$3\Y5< M[ #O>XPKI@>]?O^-)EIM>7AT=<1FV8-,463W';& ML>1744?*P,-CP[(TYIF7?K$UB'F8Y2\U.A:=*CBH+NJ[C^"#[JQ0A*Y.&Y56VNII[T5377T7M MA>(HV[*[UDHW?]?W0*K>QH$715?SFYC[/T9K:A4U"Y$&$F9OC5L, M/C9/EL)(,=+BP.>@Y>&;*E O+T_4_]:-7]5,.,E#WN4I#SUJ]81&V>P&$U!B MAI>-JLM\D:(CV),2.+B[:KV,\X/]NR&=AZ'Z'@79PB6QO?>Q9'*3G!=:X26# M:E-N%L2"7*MGB"0%D!!WT_?V5X)6:MX)WU\]H;[OICK;.Q,;Y-IL@1<,J,NS M00R)Y509%V,'[6[="7FHY_P&N7[_H;[Y.MU$D^]_EEO^!U!+ P04 " B MFBY4^DXLHYH% #Q.P %0 &-A;F\M,C R,C Q,31?<')E+GAM;-V;77/B M-A2&[W=F_X/JO6EG:HQ-LFV8D!U*DAVF^1I@NYW>9(1] ,W*DD<2 ?Y])6/M M\&&(O1]-M;D((/0>G5>/+,NR.7^W3"EZ B$)9QTO;#0]!"SF"6'3CC>7/I8Q M(1Z2"K,$4\Z@XZU >N\N7K\Z_\GWT>5U_P[Y:*94)MM!L%@L&LF$,,GI7.F0 MLA'S-$"^;^OW1A_07^OFVF@ %+ $E&*I0* _YH0F[:@9A:;(C^,_%;86,K$NS!-KGM5< H#F"#S^F'0WVHSQHS/ %,URP=5SK\9 MAB>!PDO.>+H*C"JXY/$\!:;L:YJS"1=I[L5#>;>V9P(F'<\$]FTT MD]&;@0[T6">06F7ZR) DS2AX*-APE D]>IC*:]_H@BT!+!6P!!(;QACX;IXO MUF2+XVMHC5>/7LN$A =+PH]E G"A:ZD M/WEH+G5R/#,U,37?P02$@.1FW3D'T\YSUO.LA+SF=P"HCQ+H*TCE-X&X$>W% M0-8[[<7Q[R4@>6W&\-?6'L$+VU MX9[V(3#MZZO#Y9^PJDKQ@-A!F@><6*J_.T;5]L%(]W)5F-L:!QEN&RC0M5J. MHGL G;%VGUSJ55Y=ACMBAV'N.+%43QRCNC8^@"DQ>RM,W>&T,M1RK8-,RXU8 MI*=.(NVSF(N,B]QY?D76XW-]%EGU>%*3\#.AG 7^C"_+_ZV3_*\)A;MYU8N5 M-E/=">0"5G??_H2I@>#. OXH"-+V[6%\=I6-TDT UF\ MF#X(ZY$N#> LY5(WEO#9#T(X^EK"T0]%./I,^*3I,N&>?GLO1GQ1:3__J-QU MNIM>+-O09;;Y6O%>/ C^1,RS)5\">"^&ZY3W#%G4D41 M7,>\8\="=FTWR\Q)70&X#M9MC8,@MPU8=*YM69DG\>C#C+.:U[?[.@<1[INP M&%W;IOJHLU3 S/WB.2NNXBH]YG)$["#0 TXL5=CD@B$FP M&M(RI8,\RVQ8F*YM03T(,.,2]'(NOW]E'M(5]Y-)]3GW6 0'X1ZS8R&[MO.T MXZDOY1S$UZ,NB>,^\!)3%KMKVU%#B.KF M[M%5"F*J!^A[P1=JID\A&68UGUX[$,)!P$?]6,ZN;2 5II9Z)F*2F!373P35 MA%RB=Y=PB1F+]S_89#H/]CI,)_S)_%1U_8WY9WYXJ4O^!5!+ P04 " B MFBY4+-*:F,(2 !P> #@ &0R.34U.#!D.&LN:'1M[1UK<^(X\OM6[7]0 ML3M7255X&,@#\KAB"-GA-A-2@:G9NR]3PA9!.\;V2G("^^NO6[*->4-"R,Y, MIFH2VWJUNEO]4DLY^_=PX)(')B3WO?.,E2MD"/-LW^'>_7DF5+WL28;\^^+G MG\[Z"BI"94]6'<;/,WVE@FH^/^P*-R>9G;OW'_)0D"\6BH5LP<'@J;.4KDL5T>*F6A%A/Y]G6CV6-*-K$JEDM>E<=69FLD Q4*AE,?B+I4LKFY3SY^HCA_ZC+JJG[/] M MRG: KS/$-F_G&<6&*J^[)7ELEX]Z)H2<=7UG=''F\ D7P0N,AP^EM?("@H$;*Q',@-I1,74V$+'TFTMK1Y 3EV<9:?G$\T M^XD9ZW?IA\*\ZH57C="MJ;<&NN-F3!,O>>4.?NAQ)H@&@)'6 Z0A>[1\BB=P?&&P8N MM[DRU82Z&G*GR1^ZH?O4D=\B]TU1=E_74 MZ8"*>^YE\;E*:*C\^(O@]_WH$W87Q)VAH97M,UT*)GZ0=*'\H)IZ[?I*^0/] MI>L+ #W^8@5#(GV7.^27@OZ7N?C7+]91X?0L'RP:J+1ZH.*3!TIU6X9.R.P$ M2 ](DY7\;U:U3I+W'AUP=U3M ,M*R9T_H-ZI+GLT<'=]USF=0YY/-\U. MXY*T.[5.H[T8G,*.P&DWZI_NFIUFHTUJ-Y>D\4?]0^WFMP:IMSY^;+;;S=;- MLV L;@/&SU3VP9%4OG= +G/U'"D6#LN5*;A2@Z[#F9,,L6I%S>7,HR=Q9JX MU2:9\]2LTJ+U;G;V:Z[2\61B(3&/8-:NN.JJ=?>1G,F >HD@ZG/%LO#%9F X M/PH:@"&YR(.X].T0Y73*BUG?2M<>TJ1Y?I9'4"[>..9%.&8K:QRDT%WCID/N M&K>MN\[KRYS;3W?M3S4 J-,B(",[( B)52*M.V(=[CG[KP]@ZXIT/C1(2GXG MLKM6[Q HMBJE\F(X=T99M'R(WR-W+/"%(GOQ.Z-@^3"I"'N FD3H8N;L5Q=' M%F*Y<*O-IX:QJC85$,1$B,XS?*BJ#AJ8T+SOT-$((&)>YN(_U NI&!&K?$"P MW:PT>1,CVQE@635^&$YCZ08 M"FTY@PVK4'@7X:Y:B,"L%F(7#P$3YI2X M),5-9(*=JIJ1R-1<@"< PK0-/+UZEUC 1EHU/=L7H!:U6-+!D+H?>DJ,ZK[S M++V'NRD8P5 L$/X##HN*[Y*Y]!%TX$+S>5TVB'E^IOZ+X/#);H9!\A5W&91A M*&SS#0$K6ZH43RH+,?8](ZY#A\THS&=K3#T1BY63K'58+!>+Y370^!*K_61+ MB_VI>G\K+O>>E@_$%\17?2;(GZ'@TN$V(G\CH\1Z ># #N%I6;9O=.OK+(O7 M)1-N5W I_PE401"X_@@W$%Z9)),"E=SXN3%EM.B#'VA" M?K,FJ0;Q>38IMOL6;+_7=0-7*.^:XP@F9?3K&APQ:W/%?5P\)#>?B64=JSZI M/3 OG+$=#U9YY+. %#<&I!V"\4**A<**4,U&ZWF79*C#8TMT_$=OX[E_Y #< M4[&N;8:6N 4G@.N\IVV[%%>N+[A#5^7S+ #OUH<.W?_QX"G^SD6I9!V?S..( M?[PAN<)PWXO0@^&=0 #A>$!=PH;,#A5_P*@/*! F#]#F1O'@#Z'+8_ M8TO/42@;1HFWLD[&@;E__7)2M(Y/)6#.94'?]QCQM(V2G@]XJ51/:$FT&!=5 M#>H]B7GV3@X/]V?9]LDNT[4/-+[%V3S12RH6C[)'1Z72V][6+O>V5O%VYJ+> M9_97 BX7H0%(/EB/Z(9U_2'I,M=_)+RG"W7RYDKVT7N7FIZDQUUD="Z!ZQ7S M'.80Y1/)!Z&KJ,?\4+HC(H%K9&^D1X@:^%W E[$>?3-T*@(<0C^"4&\4E_7 M?O,?L1U*;8YNB:PNY*6C)YN76S4?$YLQ90_.&*Q3!NUZHGY:>IL!RN].YTKI M16O]L^ *2(:>7NA%IKQ\MF[M^K[;I4 N!;@SM/O7NV01GK^RM6"[D3(_[*:W_M@BVN0AN!4.YC7GL.@,) M-:]H]7J;6VS?T6)8R9F M:R=0EO,\:LD_AH+R,D6][K[VUU"IL^W1;2C1=24 M,F3B;2F]\E(JL6QYS][N4HKZ7'LI;=W]2EF)QL]A CRE-':@AO:&+%SSL=\# M,UWLYOP88?0?-+7C*3&Z-8(6"V8[9]V\ZOY2!T^.FNQ+NT]L/%:SJYV_UT'B M2VP9=@3%!?WJFX7MT0"*]N3.-F^_'Q+>1-F1>AFP2/^].D%!2P&F **Q*GO1 M_8I73W.+M/?(*G:U9-K0,'S>J5==URR&&C'E1% RR_^TEQRW"?"3#C C9+=IK-ZWO!(DQ^\8&]!-RRI^%RQF_""59O/7: 3,7 M5_U_??'5\'5BZ"]#_YN;9ZNA5HB,"3@F@7X+>\9B1):B!%DHA0A6!R;(A M$S:'5@%,2;?XU;)RAW-2';[));0C.31%%GV.XW/[.\'A;L70)"I?3 3M(GC0 M]!P,J##2'1%;[^-"CU_!!F,ZA79J\Y1+O1X!WGO<%K@7_J/J8UPFP U5*HG# M>MPS1VO,?E;A,(XW3&UFP5>K4BJ1/62@XU.]IQ57YOI03H"'-7B08>30G&/F2. )>[BWA3DR=F&[TAY-PG=I?LZMI/JPD\!K3H[N+/Z\O9R<[^T2#I.8 M$Z7G_/P3*,^Y2X,-9E8&?DI9I%T&Q &+U'VD(YDQ!S#QZK3$>K5]UQ?57RKZ MWVD\H6 XL7F2CX!8GOJTW9M5?OYI=QG"(!] K1OT ]=8Q#S._FS@\3),.?() M)7$> +E$S<9U"^UV8@MSP2G1Z/4!T=(3\@=>KYY(.^YO& 7%_7#P"] M47(LUR%R36V*CP'*@GPRYX71S/I*/#D.ZIZ=DYLH &)8)5/$IP,5@'<38 M;H=<@FZH_8;S&P$&2%.Z +,D[T'BV@ ?3@"A,V>27+T%*#&\HG32FF#*/R!Z M=6F["0BI+1>0LWTRIN]>-+FI[_$D2=1LF@<."![O=] T [S=^ _:9#64*98T M90H'$\K&1-\TP*'2BLFDQL4YMG2 6@M[T\E^0XZY(>Z(_'I4+N?*IF?@##?* MOI/,XZ#^)!IBJ#8!Z\3U01=A3@G89M#W7*B.)TC: .M;:\H.MK_&]LG,'P%Q M>'6""W:;$^M=HB^#I"ZB;@PQZN(4!.D1D(/G=-ZG#UI! _L!*A0( DPY!*YP MJ=!=242MT<0.RR\ MVS=(707G/,0BL(;&$73073*>*4B-=7P8CV76MDIR;&<(.@#B2Q)ZQH9U7H=R MP)CW/L[88=(6/$AG#$_+7\>']N@,@*S4E[@ UKK,&/P,\0E,#?[@7R$HYO3E M$GB6#43\")T.G6T,?*HA7S 0JA_;#S3FC"B&7GO<-3*\,>SS+C"!!>ZHH1N4 MKG1B,?':"-=4)DM5*IX)CUG?X09X*O1F"KU\N^IR[>BQRCK]UG#/0LQH'N M$W%(R?@,QU-LPRW(HN3N9Q#V"CD@DVNJ-(Q?U4 @$.[J3"!ILG)\_ MS3EIEHDM&:BCQS94?$4V.H;)+V8CH%OH&KQ=70(;2=OU)>C*G5-QL?FLS;O( M*.:83H9V<: /00GF,HRJ4\\#4T>K((!\;/4Q\FI;*1W),=8KQ/ M*6KWC;):P#B;"2#S0&7,1;%,JU1 ID5B]%D"Z04U_7AU<2_%W,A;Z:-9Z2D= MX'RZ##_W0K"Z).(2IRG[8$QJE0)ZQ$%SW8F-42WO(]-+FT]:Z4BFC?@H&A2Q MQ\F:HP?O],6:ZQ,\0-/*I/51*B6C0Q MHRU72 OD[/@(3V^"WQ<>B8BBR.G9:>#G1,A>3_14ED4;QKHJV7>0&HT1$\F7 MCC'L.?M1W",:L#H]8JJ[XDNG!8))>=FXR]9;U]>UVW:C&C]L/2T08UU1:F#T MX)BME_AMG22^PV5)?)6=)?%IR,XS48QN*L-R.ZE*$7.<=07)7YCSFYON$2[< M*7PJH"^72(@7024NP63^T9AOYBR/V3W^^&@HELR9>JH8S'Y<($#'XHZO=IC= MB)W+ NAT;(WF*MW$07F_K/$!'\.T3$B:ZIQ8WQL>1,$AKP<;SYI07J MVP[8J]R1TV[^=E/K?+IKM)_B4FUD:-ZF=AF,/_I7R$5D\:[KQ0,%L3 4=;NLO .>G%P3CM5D05T,L,T0O1W0%Q^KZ BFHV[CI['Q;E,T>OR64W_4G5?SX(PU\]7 M#45G+W;_)_+:9M;0^U'UI::QA=-K*Q*"-M2A>9DGER)G9O&1"KQ>YP,3'@5- M]O?.#\I\.])K8R)C O%NV6H)6=](N@T$ZV,/NZ5IO<]9#RS9^%JZEKZ63NCX M+CK"^F_$K>LAG>7-WRG5?\7TXO]02P,$% @ (IHN5.U7=X[<(0 T]:W/:2+;?J>(_='GO;D$5<6PGDYE) M/*["0&QF,/@"GFSNUGYHI,;61$BL).PPO_Z><_JAEI!X)$YLSWIW9\> I.X^ M[[>.S\<7O9/C\TZS?5*M'(^[XU[GI///%X<'^X?'+^5'^/ZENH =GP[:']GI M66O0&PQ_V?MPWAUW]DY8M0(7M420B.CDN-W]G8W&'WN=7_;N/#>Y>?O3_@]> ML,>X[UT'O^SY8IKLT;,N]64S'EU[P8LDG+\]F"?OF/H\"9,DG,FOIF&0O(B] M/\7;P_3SE,\\?_EV[,U$S/KBC@W#&8>5FKWN6?^7O>$%+BQ.GW?9^L&.SHX.F(U^!$@/N-+-A&,SP3LR673*)RQ!-9E M24C_;K $%JU6_O&WP]<_O@-8'7=/1M[GY(8U\1;X)SE^V3U!Z. E/[VK-]AD MR7@ J\_"X)JUFOT! ]KLC<\;K-=K-1AG[_TP\ES.?&_FX3Y]CT\\WTN6S EG M\S2,HO!.1"N+70Z[%\WA1UAGV&&U[KA59]W^N#.\ ) TQQUV M/NBUN_VSD5F\+7Q^QR-1OGJU4K.7/@]]UPNNXY6E%=A'5]W1J /0AV^:'R^: M?=8=]9K]]HB=#IO]UCG+/*T5"1?@/EIX<2Q6'@E(X>[,"[PXB7CBW0)FK@'$ M!$\G]'U :\1]]67-"UB\<&Z8P^?<@0, LL)K :"+V)T'*/*2F,U%!,?$<\*E MCHCC,(HE>N(8F!V(0#ZD6K&>D@-^,[NEYO4JUMD"Z">B.WLA#U@[=!9(''&# M"0Y;!#K$WX;B-O1O 9JLAP07Y7[NQO$"?SSEP2>Y2_O72[@^A!W/>03(@E,* M(%* &-'S4,Q][@A&QP,M=,?4"@,=$^.%=?1]EY^5)L:@[ M//H6 N?JY /KLC'KLPX;P7\[\/?Y6Y P5P\N83Z<=X:=YDB2@.:Y!M,LH+ E M04OXL3&F$),HS!3*$J"> F)JX+.JE0QO2&8(,BLTV V'>PB0@$$OP"??\(0Y M(DHX(%H]H7D="2*%K"3LA[=B-A&1%(5'KT@4'I HS,K!!HM$G."=#2,:\;3I MM[/0]::>_/IE& $+S><^+5DD16&34;BXO@'9N$A8$":P=<=?($P)*-4*;I-( M.IRN\E_^5%G>>X?\[R6@N_^$M0$RLYB6"!$1=QX0O:9X %!"*B0KP"50<=$8 M#LMF@@>(;"4A\)D*HW2_6 %R_=V7Z.QO0[>AW*(%3E9#F,\C#[ $9[CV2/R( MZ50X">&G "+UACPS0ST1+A+ >H#(8MW 2SP0P%+"@* #U9A*OCQ@6&T*B\X7 MT3R,12S%V.IB#=HHP-;AOB^AG<'^ (PD+X!%B5B5G'.M+>1%,3P*^(9?PS:N M$0YP]L#QYJ@W9N$"M@4;^9\WKU\W7K\Z:OSX^M7^CT>/"(.X>\<)(Y<'CI!Z M#"$RC\);+_90_L/V08:. '_P49DU^P<_H_PD+LW_^//^P5'-J=>\.EVBM(E$ M5K5BR0I;Z '3Q![P.Y((B8!B#,.O(N 37V1OAJ\C9#HZ YQHNO!]NL(FIHV( MS9S>$<*ELY>H.[JAMJ+?4/3-0B!CW,)2@A'$6;4BB4XBOEC[?5^\PSX=N%#, MYCZ);+ B[PW+ED*H5@B>H*D\V(@2;"0 .5[CIOC6.D5*U)+GX;8E)/D4+C3P M5:)&9 2-V!%W#5 KDS^LVV/0F?&4TZGUC@!HL"-BC'DD@(#PL;#M#'#>2'R' MT\>#[P(^+T2I"RC]7*\UUZ,URWYS-4*D0PE.%X364A3FVBZ M?RQB)-5>]W3 ABAJ:W'H"V SZ5Q% DDYUMC3RB/=U'LPN-'SJ,OSFP<258P& M[X<9HE#JMZD,DA4UK%F]6LGR.GMLK%X(U03D*&:2/QGX46Y+> %1C@4T>XZ MBGU$&A>W!V)3[ALMW(GOQ3,(-BRE9]Z$5LAXV>[^#M^K.%FU MPNA_QW,6)TM?9'U#,5O!$7XU!^?\Q202_-.+B0#I(=YR_XXO8PRH'9\/V:C[ M?X#L5WOZD12G>_NWG^D_>^Q#MST^_V7O\.#@[\9S;'4PHO%=@GC?AL*DUXAQ M@4MR$;G1IWD4M?PP1KYM@^"L5FHVTE?]HJ'@TZD7S?"&2ZG1LWA-0PA\[8W+ MO DM/L]AV5C:<>19H2I&RXTDN NRP)%2 F C/TQ$ '(ZBCX$\(G'S-E7&0DURKSHK2 M+Q0G@76UTV^$H9:;TCMB9PL.NTB$R*OA5AJH,F$@\Q#R2G,Q(MA2M7)WXSD8 MLF(>PH]""1)_CT5K9:(3\@3O%]*2I]#B&< +[F CH+=8!D2N1LT&^_7R(HRN MX8?6#4)6QC'Z^\U]&?10/XZ MGRQ!+,M0$]5/;D!1H.S#]8!N _<(=GX1PBZ MC/F" ]8C0,"U4 $]^<,D##]%BR"@V!I^G;=MG:2QVV.,";36>,W%(H$55_F5 MJ!@\+D/&/5R^J9?/,>'^0V.^/_C08&-$__O!L$,6*_(F**8HPYPHY*]#I .$ M'T)+$OEU&,JPT2WW%^@C2MXV]S>48>D(;RZ%2;P WG4\$3A+?+AD"51^J.,P MK.Y\"L([7[C7:"(5.3+J.D0W8GD*K!C>Q6\?W-@8=5KC[J#/#O?14FHKBQ8) M*$8K:9^U5F)8BQ@=(14OTS:P4O8U$S_35C'X/GR&?K@6- !7?& L/9\DK+/X MA@,;F6!709R+)..L+,XE(Y+*+E60KF&,)7)]$<<28S+\3JQ@;*%8+RYQ8PMC6,33 MJW;4/NN2O4 AV#C1\E9K.\P,;%)<$X%'G'$7T)PUD0K,-BU;2O\Y%*G%2$U=&E_KD-G82#L23!-!O$K2R$,! M!\OX>MG-O+.R6[#\%Q'E896%':(I9QG5-4I%@1D)]TC>F/,E[8VR'!A/6JM= MOH_,]D!B#S;+L ;*&[PJV#$V;H!OT:V.M',@ZHSI\^56Y,]?#0B07^-"7 M,B+1R$4%^F'P O@L #6^YC06W5TZX'A!\)-%\F(KD3(EA)UY7LM%K9<:O*9#6?D;#> MO"LM8RG!1=ZW1N*U:/<2C-Z5,*=VJ3$H."\)"JY0)[/)#_R2/<52Y6+U/@L$ M==',D=[YMQ64PU%G!N46G& M*G2-)"*I4'[NW:4$X4+&YDJA\'A0S?9GG77P1+(24*J8G6@*'[8" MP[X,T[@1*T@%NWY]AF-MX&&%L+,!B-A$(/*A!4*%CK-=CA<(*A!,\4'")%9@BS-52>B:&# M8:URY+Q43"OM4KI."3[R'#I9:GU$<0&TF9%MY]*J0W6,#USQFHOT]F:=K?3= MFNU]9[5E5P!XQ!C2J2,O$NP560,V"576%+ZQ\+*&111R$"WPW&J%?((\Z(M] MA')FMNAMJ\-JQGL,(9K;+4,T&0!)(,[YTKA5-:ZK/RA-Z40+52^]")3[A44X M<6*$R^8XARJ8WAP")P*8J/6Q&I-H(.L,67[7.M8E)V%H'%BD]&RGX\K:]$J\U$%K2$%,B"F5+ MDW)K)B -'Q>S.5V0AR-":HV:QE1,**O#Z%*,LR:^*=>SX:<E2Q!*E6B@+$#@:'J;1>]G DBRC-]EK5@)0Z*J=" M%7[D2PH[HCB3(:[UFAW65UN7-1[\7)MN2)(\/,;!&-M:&N$? MW(XA%J394;]8/(%7E>K>:D7G48A2ZK)8!L!.]0-*:%."$U76;CD&ZADJ4"76 M:D@T.S^TQ!M<$Y_,;J-:,5I)[T/'&$L>+4V3S;NC*A?3+M?87N0\Q:#BJ^>@ MXK<2"1,95#1&H_+$,*4LJ"LTUQE%J9M\BO@'>$S-VZ+V7[GBJ:VAM.W:Q/]R MDT>M[0H[VG0GFQ+S)E )FW1,=:*BGRV;H5)(S,K33&F MX5+'"50V"Y9PA2\2U1291)Z#E5L(34S7NYY#'4KX>4'Q-J7)9/LDQZI)78Z> M&D#B,Y_-??$6*'TT'G9_ZYQD'GS\4GVKJEV ]%Q9P.&&BXDO7I#]ZI/BO)^- M %8U:4W""!ZN2>D0Y+-<%&6:BVK-^FGOI'A#B'YJ08G$%*. TMPAM*CD8-JO MP9.$8ZC+RO_J$1!-F=HJK+V+P[1!-Q_A*ZOBN.\@]KV(QO>JHI;?AIZLF0(* M1K"JHA/C,$?4/[2NP]1J))ZN?RHX8]D:&%,BQ-/O,RMC3;MS Z?_%%MY;U=@ MY)CP;@H/<&FRV@1(-3=.RPHV\_96_9ZE]7J>+JA/4PYQ0 MZ+.D[D<&B"B[6]H5@@Z6W(W\[4YN)"W *YS[@+^L-FGJ9Z^ONT6#[.$KV\'@ MV9ZZ2:YL5VJE8;"F]:TN"MMVL#,A MB19"M?9%U >%,A$V-<-B1>R54K$S<)G#B,(YZ-;*?D[@0WT9)@S5G?J&NI'& M6>C:#20V>-\A2^B\ 3D,L@ X4PI%7Z%1GX66#:PEP_5AA[(T@%H-90*..KH# M.5P"W1=2&IAW2Y7CMP0'ETV3Y.;K/4Q#U6P@-_,H.J;0P@E"UKE5GEA;3#DV MPV&F/G2 MX:BTP$3LL9LV#G&^RS)%&0;NU]@TK"9KW6:4($7G3-"VYW 7JFXUC0TV!P^+ M/0"AH/D%4L,*=)VC,/ <-A/)3>BJ0MJTD,MJHT:!JLZ: 4R]8=5;EUM85$61 M7K36V'JZ0=[7ST'>;ZCG-WHA[UAS$@L5C""3(+9L BD4FM1Q]E!6['W;;M2Z M4V"\E;@(V=C$7\F(70<(.7*RQ(K%VH95\]'2!QDK4M;N;F=%EGA@W]J(?.BH M#=!43UP#X@9ST%=A$&]0Q@6JEU*!$P$_3%7YF?!3(TRK%1LB97X:%IHZBQC+ MKT&3:I4;RIUEE/59&+I@6F'&W$&T]7J71% 8?]+32N7<,#(93 T(QVRW4?G MF!P&Z02*7VX9ZZ$+'JE'U.8?;85*[55R:5-)V<7^^TKU$G==[&Q,*Q*VFDA$ MO+Y2F[*K[#.%TT^#E-VZJI $QQ'&JMZNQ;FNJ>4#)& 0<*AB1J4DK=_WIWP MJQ5#CYPF&JE'I:UXQB!3=50[X-[ GRI#8GVP!N4R:=Q,^B4S@R7 #YSC( FD MP@%.C)#!:AG@E-:G/$BM65=;7DJE43O41]$9F$3/]L0B>2WXT0K''%$BI.&J M@Z[VZ<%\AD^.+Y4R6+IA- _U8 M@%SW !C:- TZ\/[EQK[!K[Y;[ MO$3&]4 M:M:J9=($DNDCYPLPB;'!55? _K&(O-CU3&@XNU16:UJV/+_EGJ_R'3FVKE;L M9Z(E?639R-\) BO8(8K$MLD)=J;IX'5-F/;H_!W@/GF!"OJ2EDVS[45-1@SP*:%R?*%S^^HS"Z3T"NHQA8FA#;[4CJHM?; M KV T'8A_Y"6L:6OZK**N2 $D/*#BZ@80.Y4>HQ+6*%:H74[!K\25*IG>H69>KB!YD)\H>Z M,TB'8KFI,CBY- ;0]\9F_=0O":4TCAL65 W,:<\*9EB:1G?#!Q$7RH#T2JPR MAHL+P$@UL5+@YVY'8JI69,AJFU$BN3%^25HK?R(CNA^\@*8FR%Q1&KK 6-G=&&$9$T1--Y=C+':T-8IL M"$7$:46LLAVRDS0VI&,SWGA:U!6S-[5)W9[>^T9UZ#\"NW(J[GJETWF4X:^ZE!7BM S;4,R0FPE!O58 M%CG893%7%FDHGY&];4U^4?>$&4Q RO,)HLH-I:Y#-HIGJ7I "_"Z8MYZ'P"#C*--6GY6;5B7>U3L,D\7%]> MSX9)TJG*.&\;&\7"*-V(FQ_7;*8KJDFAP6WHH3"$1UI+N^ K>^JH9#RJ""D> MF.9=4M\&SFT@A;DNR#.^T,I?8*C010JK%:V5XW?B.PLXU0 M-^/:BK::HH1HW54F=1I)EPK-"U)/GD^ #:2UM;)&.JN+7@G 8TE]5M!!=0W) MQA<]G]P Y_ 3O+ <% ,5Y*?#7!0W/KXKY[4IX+PA0^R(&(J26.9^U;28(*P MNE[XG%*MVDGP3"&L9?E+$P:'HK)EN(A47-D,P1>B%=?/X=5^B2>,C@;TTO? $644]MML-9+Q MH=77'PI*^L8/;[(^#'3T1I\N (^GZ8@,&Y M71T36UO&9!QJJ_F8F86P@5PV&).\DNF];0K;5KL13/#E:/_@56DS @9:+1UV M>/3VX(#-]V?[#8+'QS#ZQ%JH8^1;_$"7IHDD6\,QZ3CN;+I0LAXC(EL8*0\O M@'PE@$Q)52J?OYN?F"_G*O/OU@WC('<*)4?1B(/5=Q1A%-F4'C^BZ>4_JE8( M/;Z1FC9=U7JI0]^ETY&+)-(C"4IR&LZR2SL2*0L3)BR=I5^'4_45.N,@;T@7^MXG6'*&(XI4&:O5_5\R*!M'\.L:'F[M MO.2NS !^TOE%(\$?''&J][F0YNSWV1;1GNQSM$NW-IRW08DMRG3>T.1V50M% M0)RL2UFJG)@V)+)U6MC_9UYPBM(+[0KA[K,/TB^2;T_6F3^0T:CQ529'1;OE M.S$V6 56_XIUC2MB)_(F.H<'>W/#](S,/F(,MI)4.9CM2J>RP&4#Z^TW!76# MVU!39CJW'M]B/W0XV?\/ZO!4Y7] 64<3ZZ;=VL=W*]'X=+\B( M&B7"30=LYBVU&]Z.4<(M];5J]1%(9AAB2:R#=$@ MK4O1+X-V5.4/V%QBGJ -WM"-) CC:B4(;\U[@U"8J&9,W2Q<"GF\VUR>@>F# M&\/:"/N)C+".*0"AZ7II0X+QQ@M@K][[:)Q>>LM2>J=\VP$0G)[0G>3;5V&Y M]#?[UGKZFF/*4LJX"TTP'P]X,A)]H$5 M45/HVI#2PDQU\#2\9;>$-#*=()C1L#31W)W6-558EZ5+4NW04H:MR]3OK8D7DL8F(H'++XZ&:5]07'37:VQ$3' MLG'%C-.R.W;BT#JO-5$ "%V^R]&D;=P%VC[RY5F>2\%B?9\R&.D'RZ)!;W%% MFBE+$DT@]'E4[4@:#,-:B#2<[/.[_8W#&8QI@]VW.)("[Q=F1*LE%VBU6-4 M GF*.^Z7"?-].N@C3P4;$ LNO1 M5B^-Y^J%#[H(QC 0(LW- M:HA'(,Y^WI>5*SA/F2H39$U(8=#TI[7C [W8*@S5N0WMYJ1O+O54_9=Z.-*4 MX)%YWUGCN'O"9@M,0\3T[\#U:'#QP^M4\V*W X+9F2D1[/&[=_C*+BT5@-A^ MMVP1?WL6Z?C0?#<0/_H&N; M+?C0'+->\P/> %]W_O>J.Z:[!WC+A^ZH4V>GS5&GS:XN!WVX>M@==?MG;' U M9H/W>.&PTVN.X??QH'B7H_-FK\=..^P,M]:'*T\_-FCOL(?1>'C5:=.G+EJL ME\,./@MVTFRU!L-VL]_J@($[/J=W#^)&1[@L_CT:P[+PH5KI=SZPCX/A;Y). M)0I&0+:'!^!]-AC8E.E[3\#J25^$@LO"+7#E(=&M>G)KV&EW ;QGPTY' GK8 M@2W!?BX'0SKKZ4C:Y:Y\SLH7EYV8&;V^H:HMR+ M*]@XP G_W0<\D/!><(MZ2^C0CWJAO[3<1JZY.68Q 8YH#3^=C4N8. M Z7 4@.2FPE?-'09=")6]J=U=&71C!U[T+_&S_O7F HTP>*0<\W4MM!?D[(, M]2=LF$(3B H?NX'WQ*TO1Y',X M3>LLMD)"+#S(9,7@,5ZD R]H0NBZ:VF4+'".C30@31%UPTK9R1)E:LJ74\15 M'?T*MUGG/4I)N)2B;0HF!"D,@HMQDQ "C\?-TQZ(VTZO-[ILMD"M_+)WL$>? M+YOMMOZLR. U4L$IZ(3.D+Y6NY+?O #2Z34O1YVW^H^U^,@C#XE#DO=X>*+^ M:.N%?_S['O#!N)W^\+LZBCQL2JCZPNS]AT=?^8 ??];?P_\-K:UJ&%A\YM$K M==^2NWE]R%^ ME1\_^!D[4>!(?SN@_^PH=U[&+]DI&),!^RVU.?KBK0OYA1,[+@^\,RL_SEL'O1'(+K@Z9YK3MN MU:7_< &6.[H%YX,>ZH]1*J=T#<>SG'J64\]RZDG)*71&R%0\D4Y)L4UJ.X#E M9GW&KWJ"'MIQ]^1?:0SZ$CU1= E6W825Z!MZI3C]]R_MWSW[&7\%/T/&WT97 MW=&HPYIG#5#S'R^:?=8=]9K]]HB=#IO]UCFI]>)!JGRE*HQ>T]R-8QJ+<\J# M3WJ8ID[TK!OX]6PS/%J;X7=OOO!9^X:[+E]G--P#JHYVN.;):.^O-5NR\']* M)_]JNZ69SB08J>D%I:;;LZ1X<$GQJXACS^'LC-_RZ%-X&S^+B^\O+@J0\)2. M_XUEQHJC\^R@/#LHSP[*HW-0S@:]-OHCHV;K'+R19O\W[(25)=0KGH=V-'+^ MQ[.E\&@MA3:@Z@+SLFM-A,>IH;Y60=MG?TKG?M;,SYKY63/_UVOF7R\O!L,S M4,VM\^:H0ZJYP?K[S?UGY?P74<[GPAG"5\ M5M'/*OI913\Z%:T4]&C<[/B)T 3NPG-G*\,':\M9G!QZDJO]9,R!W_*1W]V95_6#OA^.7IH/T1OCP? M7_1._A]02P,$% @ (IHN5#N5V*TY!@ Y!$ !$ !D,CDU-3@P9&5X M.3DQ+FAT;;U86V_B.!A]1^(_6.S.J)4@$*!WB@9Z941+U:+9[=/*) 8\3>S( M=J#,K]]C&RAMY_+2]@GL?-?S'1\'6I?#JWZ[=7G6.6T7"ZUA;]@_:Y_]6SDX M",)6U2^Q7UT:D%9W<'I/NA%9JDV(!1B=,&*;:K=/>-W(W MO.^?'9?F/#;3P_U@AXL2H0F?B.-2PL:FY&+=K,Q2JB9<5(S,#FN9.2++]4@: M(U._-9;"5#3_P0[#I_68ICQ9' YYRC2Y9G-R*U.*3)U^[^+ZN*3X9(I4K6[[ M[''*1]P0VQ9I5;OM5O6FO5' 4_1=!']1SJMJ2NW/8J2S(QL$??^JC==^J\(B MAY0%P0'7N[H@=[3:SO\+C4'UP, M/'C/&]A('=;? $(+V@G*()>,)F9*.D+(7$2PN669XA$7$R+'9,A42OJ2BC6H MO\!C]TUJZK5/9)I1L2 1/A-F\%QFF50F%UP;'A&UKJY5[;V<\IO7TVU?]3I7 MO3(Y[P?E8N$K%0$)FV6"V=4M()__"G?"([(!9)GT1!20K>O[N[-#.-O;M MQO[1=GF-5$SH!CJ8G].X"%R/U4[1SMD MQ*@BW!X]I@W)M06"(HJ:4Q631,H'[%2,=5) A(RH1LL P?:Q0@"M*F&%I5@8 MC]W!+:':151LC$HP>.<>D.XJ'1)AWY!U M)&>@R\[+YJ=H9F.2YGFK"(]"LJ0)3GH M0")X0B=UIA@%8^+ON38I:BD65A2[ZRS[ F]C1.+;I!G4:I_*P!A"0?Y^=IN\M22M@"4%O"[W)F0)9;YV9'W<,1D**4"DJ>6#&YBX68C9CB,$VJ,Q&M"2.A M$V;S6O^)HJDM*$KRV!Y'""F;+I49ATA'BF?>6Z:,Q"SA.+\H8\Z21#"MUS%P M$A05VK5J^[ ]>$A<-8KK![LJ%KR@/RYGO2[F_17UQ>VR>X3B,5L[&42(,0'# M+2JN,%LX6K/,FC%_SU# B=&N._*4B)0RG$;IQ7NS-ZE/&%>%^V8(JF-9=QX[$@R617O ME7G]3F$6MN+$:F$BQ80I/Q"7GF-EI_FB*,T4]B!2:"V6J;TB;&GX@L.">!N$ MVMJ'I"TIN\YO4>AC(62Q@./6&4,-(8R=E+DO7G9;YX/KX?HE>\H-J^B,1NQ0 MR+FB6:F=R'D%I$3KK:JU;3_+N_.4-W47MT\;YT ,#)WP4>(/^Y63B.4X_8+' MN+S/\2R5RBH$S%(?=L;!7C*?SP/[ NM!"E "@?'KW2H7P,D.M?HQTMU;YL,; MK,U.@C$.])0_<(O(W2(6;%$L]#2ED?[-X7V;Y!@R MI'"Z(%.>56/:QO+YE:+/R&JXV]L+)S<'"P8FJ5;.V%C>T_DWP_ MW*L<-)J[*\=W;HA.Y1&VKL"RU+,+Z,5(!.+ MQR;CJJ>];YC^\M^78H'8/?LW#3;=OSO_ U!+ 0(4 Q0 ( "*:+E1/RLL6 M\P, *4/ 1 " 0 !C86YO+3(P,C(P,3$T+GAS9%!+ M 0(4 Q0 ( "*:+E1=;'KLY 4 .4W 5 " 2($ !C M86YO+3(P,C(P,3$T7V1E9BYX;6Q02P$"% ,4 " BFBY4)Z^ GOX' ! M7 %0 @ $Y"@ 8V%N;RTR,#(R,#$Q-%]L86(N>&UL4$L! M A0#% @ (IHN5/I.+*.:!0 \3L !4 ( !:A( &-A M;F\M,C R,C Q,31?<')E+GAM;%!+ 0(4 Q0 ( "*:+E0LTIJ8PA( '!X M . " 3<8 !D,CDU-3@P9#AK+FAT;5!+ 0(4 Q0 ( M "*:+E3M5W>.W"$ '*_ 1 " 24K !D,CDU-3@P9&5X M,3 Q+FAT;5!+ 0(4 Q0 ( "*:+E0[E=BM.08 .01 1 M " 3!- !D,CDU-3@P9&5X.3DQ+FAT;5!+!08 !P ' ,(! "84P " ! end